Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 6;29(12):e1669-e1679.
doi: 10.1093/oncolo/oyae235.

Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with trifluridine/tipiracil or regorafenib

Kai-Yuan Hsiao  1   2 , Hsin-Pao Chen  3   4 , Kun-Ming Rau  4   5 , Kuang-Wen Liu  3   4 , Ben-Chang Shia  1   2 , Wei-Shan Chang  1   2 , Hao-Yun Liang  4   6 , Meng-Che Hsieh  4   5
Affiliations

Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with trifluridine/tipiracil or regorafenib

Kai-Yuan Hsiao et al. Oncologist. .

Erratum in

Abstract

Background: The impact of sidedness on survival of later-line treatment in patients with metastatic colorectal cancer (mCRC) is undetermined. This study aimed to investigate the association between sidedness and survival among chemotherapy refractory patients with mCRC treated with trifluridine/tipiracil (TAS-102) or regorafenib or both.

Patients and methods: Patients with mCRC treated with TAS-102 or regorafenib between 2015 and 2020 was retrospectively collected. Patients were stratified into TAS-102 first and regorafenib first, then subdivided into TAS-102 followed by regorafenib (T-R) and regorafenib followed by TAS-102 (R-T) groups. The oncologic outcomes were presented with time-to-treatment failure (TTF) and overall survival (OS).

Results: After matching, 376 TAS-102 patients and 376 regorafenib patients were included for outcomes comparison. TTF had insignificant differences while OS was significantly different between TAS-102 and regorafenib groups. Median TTF and OS were 1.9 months versus 2.0 months (P = .701) and 9.1 months versus 7.0 months (P = .008) in TAS-102 and regorafenib, respectively. The OS benefits were consistent regardless primary tumor location. Subgroup analysis with 174 T-R patients and 174 R-T patients was investigated for treatment sequences. TTF and OS had significant differences in both groups. Median TTF and OS were 8.5 months versus 6.3 months (P = .001) and 14.4 months versus 12.6 months (P = .035) in T-R and R-T groups, respectively. The TTF and OS benefits were persisted regardless primary tumor location.

Conclusion: TAS-102 first provided a better survival benefit in chemotherapy refractory patients with mCRC across all sidedness. Further prospective studies are warranted to validate our conclusions.

Keywords: TAS-102; metastatic colorectal cancer; regorafenib; sequence; sidedness; trifluridine/tipiracil.

PubMed Disclaimer

Conflict of interest statement

The authors indicated no financial relationships.

Figures

Figure 1.
Figure 1.
A flow diagram of patient selection and exclusion.
Figure 2.
Figure 2.
TTF and OS of metastatic colorectal cancer treated with TAS-102 or regorafenib. A and B, TTF and OS of total metastatic colorectal cancer treated with TAS-102 or regorafenib. C and D, TTF and OS of metastatic left-side colorectal cancer treated with TAS-102 or regorafenib. E and F, TTF and OS of metastatic right-side colorectal cancer treated with TAS-102 or regorafenib.
Figure 3.
Figure 3.
TTF and OS of metastatic colorectal cancer treated with TAS-102 followed by regorafenib (T-R) or regorafenib followed by TAS-102 (R-T). A and B, TTF and OS of total metastatic colorectal cancer treated with T-R or R-T. C and D, TTF and OS of metastatic left-side colorectal cancer treated with T-R or R-T. E and F, TTF and OS of metastatic right-side colorectal cancer treated with T-R or R-T.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. - PubMed
    1. Cancer Stat Facts: Colon and Rectum Cancer. National Cancer Institute Surveillance Epidemiology and End Results Program website. 2018. https://seer.cancer.gov/statfacts/html/colorect.html
    1. Siegel RL, Miller KD, Wagle NS, Jemal A.. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. https://doi.org/10.3322/caac.21763 - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A.. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. https://doi.org/10.3322/caac.21442 - DOI - PubMed
    1. Van Cutsem E, Nordlinger B, Cervantes A; Group EGW. Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol. 2010;12(suppl 5):v93-v97. - PubMed

MeSH terms